Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Phase 1 Safety Testing of SAR405838
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 77
- Registration Number
- NCT01636479
- Locations
- 🇺🇸
Investigational Site Number 840101, Boston, Massachusetts, United States
🇺🇸Investigational Site Number 840001, Boston, Massachusetts, United States
🇺🇸Investigational Site Number 840002, New York, New York, United States
Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-07-02
- Last Posted Date
- 2015-06-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 447
- Registration Number
- NCT01632163
- Locations
- 🇨🇳
Investigational Site Number 156035, Fuzhou, China
🇨🇳Investigational Site Number 156017, Harbin, China
🇨🇳Investigational Site Number 156028, Shanghai, China
Efficacy and Safety of Insuman Basal/Comb/Rapid in Patients With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: insulin human (HR1799)
- First Posted Date
- 2012-06-28
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 552
- Registration Number
- NCT01630369
- Locations
- 🇺🇦
Sanofi-Aventis Administrative Office, Kyiv, Ukraine
Study of Efficacy and Safety of Irbesartan/Amlodipine 4 Fixed Combination Therapy in Hypertensive Patients Uncontrolled on Irbesartan or Amlodipine Monotherapy
- Conditions
- Hypertension
- Interventions
- Drug: Irbesartan/Amlodipine (150/5mg)Drug: Irbesartan/Amlodipine (150/10mg)Drug: Irbesartan/Amlodipine (300/5mg)Drug: Irbesartan/Amlodipine (300/10mg)
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 158
- Registration Number
- NCT01625494
- Locations
- 🇷🇺
Sanofi-Aventis Administrative Office, Moscow, Russian Federation
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2012-06-19
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 486
- Registration Number
- NCT01623115
- Locations
- 🇺🇸
Investigational Site Number 840421, Mission Viejo, California, United States
🇺🇸Investigational Site Number 840452, Washington, District of Columbia, United States
🇺🇸Investigational Site Number 840425, Auburn, Maine, United States
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)
- Conditions
- Hypercholesterolaemia
- Interventions
- First Posted Date
- 2012-06-12
- Last Posted Date
- 2016-10-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 107
- Registration Number
- NCT01617655
- Locations
- 🇺🇸
Investigational Site Number 840742, Bell Gardens, California, United States
🇺🇸Investigational Site Number 840743, Northridge, California, United States
🇺🇸Investigational Site Number 840710, Ponte Vedra, Florida, United States
Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2012-05-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 100
- Registration Number
- NCT01606384
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Safety of Single Doses of SAR113945 and Efficacy and Safety of a New Formulation Given Into the Knee in Osteoarthritis Patients / Part II
- First Posted Date
- 2012-05-15
- Last Posted Date
- 2014-10-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 130
- Registration Number
- NCT01598415
- Locations
- 🇩🇪
Investigational Site Number 276001, Berlin, Germany
🇩🇪Investigational Site Number 276002, München, Germany
Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2012-05-11
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 142
- Registration Number
- NCT01596504
- Locations
- 🇩🇪
Investigational Site Number 276008, Berlin, Germany
🇩🇪Investigational Site Number 276006, Berlin, Germany
🇩🇪Investigational Site Number 276005, Mönchengladbach, Germany
A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 49
- Registration Number
- NCT01596270
- Locations
- 🇺🇸
Investigational Site Number 840001, Detroit, Michigan, United States
🇺🇸Investigational Site Number 840002, New Brunswick, New Jersey, United States
🇺🇸Investigational Site Number 840003, Dallas, Texas, United States